Neurosense Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -3,030 | -2,994 | 2,986 | |
EBIT | -2,999 | 2,983 | ||
Net Income | -857 | -5,404 | -2,950 | 784 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cash | 1,208 | 771 | 2,640 | 4,759 |
Basic Shares | 15,405 | 15,405 | 15,379 | 13,623 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -97 | -89 | -3 | -3 |
EBITDA | -12,028 | -13,379 | -8,284 | -2,824 |
EBIT | -12,049 | -13,468 | -8,287 | -2,827 |
Net Income | -10,107 | -11,197 | -2,495 | -2,829 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -8,303 | -7,656 | -1,556 | -704 |
Cash | 2,680 | 3,543 | 11,063 | 699 |
Basic Shares | 13,640 | 11,504 | 1,940 | 1,940 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.02 |
2024-03-31 | -$0.35 |
2023-12-31 | -$0.16 |
2023-09-30 | $0.10 |
